Cumulative Index 1986

Volume 4

January	PEDIATRIC DERMATOLOGY
April	PHOTOSENSITIVITY DISEASES
July	THE AGING SKIN
October	COMPUTERS IN DERMATOLOGY

Note: Page numbers of article titles are in **boldface** type.

Abscesses, in neonate, Jan., 12
Absorption, percutaneous, in aged skin. See *Skin, aged.*
Acetylsalicylic acid, for mucocutaneous lymph-node syndrome, Jan., 123
Achromobacter infections, in neonate, Jan., 15
Acid, trichloroacetic, for wrinkles, in elderly, July, 497
Acne neonatorum, Jan., 131
Acne rosacea, in elderly, July, 492
Acne vulgaris, in childhood, Jan., **127–136**
  clinical manifestations of, Jan., 129–130
  incidence of, Jan., 127
  management of, Jan., 131–134
  pathogenesis of, Jan., 127–129
 in neonate, Jan., 131
Actinic prurigo, in children, Apr., 317
Adenoma sebaceum, in tuberous sclerosis, in childhood, Jan., 47–48
Aging. See also *Elderly; Skin, aged.*
 and cutaneous carcinogenesis, July, 467–468
 and epidermal immune function, July, **447–454**
  ultraviolet radiation and, July, 450
 and importance of appearance, July, 501–504
 and wound healing. See *Wounds, healing of.*
 biologic, due to amino acid racemization, July, 352–353
  due to enzymatic glycosylation, July, 353
  dysdifferentiation theory in, July, 353–354
  free radical theory in, July, 349–350
   differential gene expression and, July, 354–355
  mechanisms of, July, **347–358**
  oxidative free radical damage in, cellular protection against, July, 350–352
  rate-of-living theory in, July, 347–349
 cutaneous, elastic fiber chemistry in, July, 440–441
 in-vitro studies of, July, **359–369**
  fibroblast model in, July, 359–360
  genetic control in, July, 363
  growth factors and modulators in, July, 362–363
  in-vivo correlations with, July, 361–362
  nonfibroblast lines in, July, 360–361
 interleukin-1 and -2 in, July, 448–449
 lymphokines in, July, 448–452
 of U.S. population, anticipated survival in, July, 373
  dermatologic implications of, July, **371–377**
  distribution by sex and race, July, 372–373
  facts and projections in, July, 371–372
  geographic distribution in, July, 372
  use and cost of health services in, July, 373, 376–377
 sun-induced, **509–516**. See also *Photoaging.*
  actinic keratosis in, July, 512, 514
  atrophy in, July, 512
  chemical determinations of, July, 511
  electron microscopic studies of, July, 510–511
  experimental elastosis studies in, July, 512
  irregular pigmentation in, July, 512
  light microscopic studies of, July, 509–510
  milia in, July, 514
  skin grafting in, July, 511–512
  telangiectasia in, July, 512
  wavelengths responsible for, July, 514–515
 vs. photoaging, histologic comparisons of, July, 517–519
AI/DERM EXPERT, for diagnosis of skin tumors, Oct., 620
AI/RHEUM, for diagnosis of dermatologic disorders, Oct., 610–612
  data entry and display, Oct., 610
  medical knowledge, Oct., 610
  reasoning mechanism, Oct., 610
  software, Oct., 610–612
Allergens, and atopic dermatitis, in childhood, Jan., 56–59, 63–64
Allergic granulomatosis, in childhood, Jan., 123–124
Alopecia, androgenetic, in elderly, July, 494–495
Amino acids, in collagen, July, 434–436
 in elastic fibers, July, 436–437
 racemization of, in biologic aging, July, 352–353
Ammonia, urinary, and diaper dermatitis, Jan., 24–25
Angular cheilitis (angular stomatitis), in elderly, July, 491–492
Antibiotics, systemic, for acne vulgaris, Jan., 133
  for atopic dermatitis, Jan., 63
  for candidiasis, Jan., 10
 topical, for acne vulgaris, Jan., 132–133
Antihistamines, for atopic dermatitis, Jan., 59, 62–63
Antioxidants, exogenous, against oxidative free radical damage, in biologic aging, July, 352
Arthritis, psoriatic, in childhood, Jan., 102–103
Aspergillosis, in childhood, Jan., 147
Asteatosis, in elderly, July, 490
Ataxia-telangiectasia, characteristics of, Jan., 113–114
Atopic dermatitis, and diaper dermatitis, Jan., 27
 in childhood, allergist's view of, Jan., **55–66**
  clinical aspects of, Jan., 55–59
  immune system in, Jan., 59–60
  prevention of, Jan., 64–65

Atopic dermatitis (*Continued*)
in childhood, role of allergens in, Jan., 56–59
stigmata associated with, Jan., 60–61
therapy for, Jan., 62–64
incidence of, in aging U.S. population, July, 374
Atrophy, in sun-induced aging, July, 512
ATTENDING, for critique of patient data, Oct., 622–623

B cells, and humoral immunity, July, 447–448
Bacteria, in acne vulgaris, Jan., 129
Bannayan syndrome, hemangiomas and, in childhood, Jan., 85
Basal-cell nevus syndrome (nevoid basal-cell carcinoma syndrome), in childhood, Jan., 115
Beckwith-Wiedemann syndrome, in childhood, Jan., 86
Benzoyl peroxide, for acne vulgaris, Jan., 132
Beta-carotene, for erythropoietic protoporphyria, Apr., 335–337
Blistering diseases, in childhood, Jan., 96–97
Bloom's syndrome, characteristics of, Jan., 114
in childhood, Apr., 314–315
Blue rubber bleb nevus syndrome, in childhood, Jan., 85
Bone marrow, in heme synthesis, in porphyria, Apr., 286
Breast feeding, in prevention of atopic dermatitis, Jan., 64–65
Bullous diseases, of childhood, Jan., **89–98**
chronic, Jan., 93–95
Bullous pemphigoid, in childhood, Jan., 96
in elderly, July, 488

Café-au-lait spots, in neurofibromatosis, in childhood, Jan., 45–47
Cancer, of skin, in elderly. See *Elderly, skin cancer in.*
Candida albicans, and diaper dermatitis, Jan., 25–27
Candidal infections, in childhood, Jan., 144–146
in neonate, Jan., 3–10
Carcinogenesis, cutaneous, aging and, July, 467–468
Carcinoma, in elderly, basal-cell, July, 468
squamous-cell, July, 468–470
Catalase, against oxidative free radical damage, in biologic aging, July, 350
Cataracts, atopic dermatitis and, in childhood, Jan., 61
Cells, B, and humoral immunity, July, 447–448
healing activities of, in elderly, July, 482–483
Langerhans, density of, aging and, July, 450–452
immune function of, July, 449, 450
pigment. See *Pigment cells.*
turnover of, in aged skin, July, 429–430
veil, function of, in aged skin, July, 403–404
Cellulitis, bacterial infections and, in neonate, Jan., 18
Cheilitis, angular (angular stomatitis), in elderly, July, 491–492
Chondrodermatitis nodularis helicis, in elderly, July, 486, 488
Choroid, pigment cells in, July, 416
Chromoblastomycosis, in childhood, Jan., 146–147
Cobb syndrome, in childhood, Jan., 87
Cockayne's syndrome, characteristics of, Jan., 114; Apr., 316
Collagen, in aged skin, biochemistry of, July, 433–436
alterations in, July, 438–440
components of, July, 434–436
in wound healing, July, 483
morphology of, July, 383–386
turnover rate of, July, 436
injection of, for wrinkles, in elderly, July, 497

COLLEAGUE, for literature searching, Oct., 580
Collodion baby, Jan., 70
Comedones, in acne vulgaris, in childhood, Jan., 129
Complement activation, in porphyria, Apr., 288
Complement deficiency syndromes, in childhood, Jan., 158–159
Computer hardware, Oct., **533–543**
central processing unit, Oct., 536
for dermatopathology laboratory, Oct., 651–653
information processing and storage, Oct., 652
input, Oct., 651
output, Oct., 651–652
storage devices, Oct., 652–653
fundamental information units, Oct., 534
memory, Oct., 536–537
operation of, Oct., 538–542
amount of memory, Oct., 541
amount of storage, Oct., 540–541
back-up, Oct., 541
multiuser capabilities, Oct., 539
networking and timesharing, Oct., 539–540
selection of central processing unit, Oct., 540
service and maintenance, Oct., 541–542
speed, Oct., 541
questions to ask about, Oct., 543
reliability of, for data security, Oct., 657–658
storage, Oct., 537–538
telecommunications, Oct., 542–543
terminals and printers, Oct., 538
when to buy, Oct., 543
Computer software, Oct., **545–551**, 534–536
application software, Oct., 546–547
for dermatopathology, Oct., 653
historical perspective of, Oct., 545–546
operating system software, Oct., 547–548
programming languages, Oct., 548–550
reliability of, for data security, Oct., 658–660
utility software, Oct., 547
Computers. See also *Computer hardware; Computer software.*
and cutaneous surface images. See *Cutaneous surfaces.*
beginnings of, in medicine, Oct., 665–666
data security in, Oct., **657–663**
factors determining, Oct., 657
future of, Oct., 662
hardware reliability, Oct., 657–658
information sources, Oct., 662–663
legal security, Oct., 661–662
physical security, Oct., 660–661
procedural reliability, Oct., 660
software reliability, Oct., 658–660
for literature searching, Oct., **579–587**
applications, Oct., 585–587
COLLEAGUE, Oct., 580
definition of, Oct., 579
DERM/MLS, Oct., 580–581
DIALOG, Oct., 581
future of, Oct., 587
KNOWLEDGE-INDEX, Oct., 581
MEDIS, Oct., 581
MEDLINE, Oct., 579–580
Paper Chase, Oct., 581–582
PDQ (Physician's Data Query), Oct., 580
searching strategy, Oct., 582–585
vendors of, Oct., 579
for medical office, selection process for, Oct., **559–566**
communication with vendors, Oct., 562–564
evaluation of costs, Oct., 564–565
evaluation of proposals, Oct., 564
evaluation of systems, Oct., 562
feasibility of computerization, Oct., 560

flexibility for future changes, Oct., 565–566
goals and objectives, Oct., 560–561
prioritizing, Oct., 561–562
informational needs, Oct., 561
outside computer service bureaus, Oct., 560
tasks performed by, Oct., 560
future of, in dermatology, Oct., **665–668**
in diagnosing dermatologic disorders, Oct., **607–625**
AI/DERM EXPERT, Oct., 620
AI/RHEUM, Oct., 610–612
DERM/DDX, Oct., 617–619
DIAG, Oct., 614–617
febrile illness with eruption, Oct., 612–614
Fisher and colleagues' program, Oct., 619–620
issues in development of, Oct., 621–622
MYCIN, Oct., 607–610
new advances in, Oct., 624
new directions in, Oct., 622–624
critiquing as modality for explanation, Oct., 622–623
decision theory, Oct., 623–624
temporal reasoning, Oct., 622
Norins' program, Oct., 619
TEGUMENT, Oct., 620–621
in quantification of scalp hair. See *Scalp hair.*
new advances in, in medicine, Oct., 666–668
computer-aided diagnosis, Oct., 667
"expert" systems, Oct., 667–668
image processing, Oct., 667
magnetic disk technology, Oct., 666
optical storage technology, Oct., 666–667
relational data base systems, Oct., 667
telecommunications, Oct., 667
voice-activated computers, Oct., 667
non-expert's experience with, Oct., **553–558**
in dermatologic research, Oct., 553–555
in office practice, Oct., 555–557
for disease inquiries, Oct., 556
for literature searches, Oct., 557
for meetings calendar and electronic mail, Oct., 557
Congestive heart failure, hemangiomas and, in childhood, Jan., 84
Connective tissue, biochemistry of, in aged skin, July, **433–446**. See also *Collagen; Elastin.*
Coproporphyria, hereditary, vs. porphyria cutanea tarda, Apr., 304
Cornstarch, and diaper dermatitis, Jan., 27
Corticosteroids, for hemangiomas, Jan., 80–81
Cosmetic surgery, for wrinkles, in elderly, July, 497
Cosmetics, benefits of, in elderly, July, 505–506
Cutaneous surfaces, computer models and images of, Oct., **641–649**
applications of, Oct., 645–648
for scars, Oct., 648
for small texture changes, Oct., 645–646
for wrinkles, Oct., 647–648
methods of, Oct., 641–645
data processing, Oct., 643–645
measuring techniques, Oct., 642–643
study surface, Oct., 641–642
Cutis laxa, clinical presentation of, July, 442–443

Data base management systems, in dermatology, Oct., **569–578**
case study of, Oct., 572–575
creating data base, Oct., 573
design of data base, Oct., 572–573
entering patients' names, Oct., 574
format for mailing labels, Oct., 573–574
preparing listings, Oct., 575
preparing mailing labels, Oct., 574
printing labels for call-back patients, Oct., 574–575
working with word processor, Oct., 575
zip-sorting labels, Oct., 574
commercially available, Oct., 571–572
data base design, Oct., 570
flexibility for future, Oct., 576–577
hierarchy of data types, Oct., 569
improving efficiency of, Oct., 571
information sources, Oct., 577–578
logical organization of data, Oct., 570
physical storage of data, Oct., 569–570
retrieving data, Oct., 570
simultaneous access to, Oct., 571
trading space and time, Oct., 570–571
DERM/DDX, for diagnosis of dermatologic disorders, Oct., 617–619
hardware and software, Oct., 619
medical knowledge, Oct., 618
system access, Oct., 617
system implementation, Oct., 619
DERM/INFONET, as aid to office practice, Oct., 555–557
DERM/DDX as part of, Oct., 617
DERM/RX as part of, Oct., 592, 598
features of, Oct., **567–568**
for literature searching, Oct., 580–581
DERM/MLS, features of, Oct., 567–568
for literature searching, Oct., 580–581
DERM/PHARM, for management of skin diseases, Oct., **599–606**
access to, Oct., 601
contents of, Oct., 600–601
creation of, Oct., 599
needs served by, Oct., 599–600
procedure for, Oct., 601–606
special drug requirements served by, Oct., 600
DERM/RX, for management of skin diseases, Oct., **589–598**
access to, Oct., 591
categories of information, Oct., 592
cost of, Oct., 591
creation of, Oct., 589, 591
diseases included in, Oct., 591
procedure for, Oct., 592
rating of therapeutic approaches, Oct., 592
update of data in, Oct., 591
Dermabrasion, for congenital melanocytic nevi, Jan., 35
Dermatitis, atopic. See *Atopic dermatitis.*
diaper. See *Diaper dermatitis.*
in elderly, contact, July, 489
exfoliative, July, 488–489
seborrheic, declining sebum secretion and, July, 422
stasis, July, 493–494
incidence of, in aging U.S. population, July, 374
seborrheic, and diaper dermatitis, Jan., 27
Dermatitis erythema nuchae, characteristics of, Jan., 103
Dermatitis herpetiformis, in childhood, Jan., 95
Dermatopathology, computers for, Oct., **651–656**. See also *Computer hardware; Computer software.*
applications of, Oct., 653–656
accounts receivable, Oct., 655–656
billing, Oct., 655
processing of samples, Oct., 653–655
statistical analyses, Oct., 655
Dermatophytoses, in childhood, Jan., 137
incidence of, in aging U.S. population, July, 374
Dermis, aged, morphology of, July, 382–383

Dermographism, white, in atopic dermatitis, in childhood, Jan., 60–61
Diabetes, buttock skin in, electron microscopic studies of, July, 399–400
DIAG, for diagnosis of dermatologic disorders, Oct., 614–617
  data entry and display, Oct., 614
  hardware and software, Oct., 616
  medical knowledge, Oct., 615
  reasoning mechanism, Oct., 615
  system implementation, Oct., 616
  system utility and acceptance, Oct., 617
  updating knowledge base, Oct., 616–616
DIALOG, for literature searching, Oct., 581
Diaper dermatitis, Jan., **23–28**, 144–145
  management of, Jan., 28
  role of diaper in, Jan., 23
  role of feces in, Jan., 25
  role of friction and irritation in, Jan., 23–24
  role of infection in, Jan., 25–27
  role of underlying dermatologic conditions in, Jan., 27
  role of urine and ammonia in, Jan., 24–25
DNA, decreased repair of, in cutaneous carcinogenesis, in elderly, July, 467–468
Down's syndrome, Jan., 51
Dysplastic nevus syndrome, and risk of malignant melanoma, Jan., 38
  in childhood, Jan., 35–39

Ecthyma gangrenosum, in neonate, Jan., 16–18
Eczema. See *Atopic dermatitis.*
Elastic fibers. See *Elastin.*
Elastin, in aged skin, abnormalities of, in cutaneous diseases, July, 441–443
  biochemistry of, July, 436–437
  chemistry of, July, 440–441
  morphology of, July, 386
Elastoderma, clinical presentation of, July, 441–442
Elastosis, experimental studies of, in sun-induced aging, July, 512
Elderly. See also *Aging; Skin, aged.*
  common skin problems in, July, **485–499**
    acne rosacea, July, 492
    androgenetic alopecia, July, 494–495
    angular cheilitis (angular stomatitis), July, 491–492
    asteatosis, July, 490
    bullous pemphigoid, July, 488
    cherry hemangioma (DeMorgan's spots), July, 486
    chondrodermatitis nodularis helicis, July, 486, 488
    contact dermatitis, July, 489
    excessive facial hair, July, 495–496
    exfoliative dermatitis, July, 488–489
    fibroepithelial polyp (skin tag), July, 486
    graying hair, July, 494
    herpes zoster (shingles), July, 492–493
    intertrigo, July, 491
    lichen simplex chronicus, July, 490
    nail changes, July, 496
    prurigo nodularis, July, 490
    pruritus, July, 489–490
    sebaceous hyperplasia, July, 486
    seborrheic keratosis, July, 485–486
    senile purpura, July, 493
    spider veins, July, 493
    stasis dermatitis, July, 493–494
    stasis ulcers, July, 493–494
    venous lakes, July, 493
    wrinkles, July, 496–497
  cutaneous malignant melanoma in, July, **473–480**
    clinical classification of, July, 474–476
      acral lentiginous melanoma, July, 475–476
      lentigo maligna melanoma, July, 475
      nodular melanoma, July, 475
      superficial spreading melanoma, July, 474–475
    epidemiology of, July, 473–474
    management of, July, 478–479
    pathology and prognosis of, July, 476–478
  psychology of appearance in, July, **501–507**
    appearance and well-being, July, 504–505
    cosmetic therapy in, July, 505–506
    cosmetics in, July, 505
    importance of appearance, July, 501–504
  skin cancer in, July, **467–471**
    basal-cell carcinoma, July, 468
    decreased DNA repair capacity and, July, 467–468
    keratoacanthoma, July, 470
    squamous-cell carcinoma, July, 468–470
Embryogenesis, pigment cell formation in, July, 408–411
Epidermal thymocyte-activating factor (ETAF), in epidermal immunology, July, 449–450, 452
Epidermis, aged, immune system of, July, **447–454**
    ultraviolet radiation and, July, 450
  morphology of, July, 379–382
Epidermolysis bullosa, in childhood, Jan., 89–93
Epithelialization, of wounds, in elderly, July, 481–482
Epithelium, retinal pigment, pigment cells in, July, 415–416
Erythema, types of UV, and erythemal action spectra, Apr., 182–183
Estrogen, and porphyria cutanea tarda, Apr., 302
Eyelid, hemangiomas of, in childhood, Jan., 82–83
Eyes, pigment cells in, July, 415–416

Face, hemangiomas of, in childhood, Jan., 83–84
Feces, and diaper dermatitis, Jan., 25
Fibers, elastic. See *Elastin.*
Fungal infections, in childhood, Jan., **137–149**

Genetic counseling, for genodermatoses, Jan., 51–53
Genodermatoses, significance of, Jan., **45–54**
Glaucoma, port-wine stain and, in childhood, Jan., 86
Glucose, metabolism of, in wound healing, in elderly, July, 483
Glutathione, against oxidative free radical damage, in biologic aging, July, 350–351
Glycosylation, nonenzymatic, in biologic aging, July, 353
Gram-negative infections, in neonate, Jan., 15–18
Granulomatosis, in childhood, allergic, Jan., 123–124
  lymphomatoid, Jan., 124
  Wegener's, Jan., 123
GSH peroxidase, against oxidative free radical damage, in biologic aging, July, 351
GSH reductase, against oxidative free radical damage, in biologic aging, July, 351

Hair, changes in, in elderly, July, 494–496
  excessive facial, July, 495–496
  graying of, July, 411–412, 494
  hypopigmented, in tuberous sclerosis, Jan., 47
Hair follicles, pigment cell formation in, July, 411–412
Hamartomas, in brain, in tuberous sclerosis, Jan., 48
Hardware, computer. See *Computer hardware.*

Hartnup disease, in childhood, Jan., 115; Apr., 314
Hayflick model, in in-vitro studies of aging, July, 359
Hemangiomas, cherry (DeMorgan's spots), in elderly, July, 486
in childhood, Jan., 80–85
treatment of, Jan., 80–81
Hemangiomatosis, diffuse neonatal, Jan., 84
Heme synthesis, in porphyria, bone marrow in, Apr., 286
liver in, Apr., 284–286
Hemophilus influenzae infections, in neonate, Jan., 14
Hemorrhage, hemangiomas and, in childhood, Jan., 81–82
Henoch-Schönlein purpura, characteristics of, Jan., 118–120
Herpes zoster (shingles), in elderly, July, 492–493
Hydroa vacciniforme, manifestations of, Apr., 316–317
Hydrocortisone, in in-vitro studies of aging, July, 362
Hyperkeratosis, epidermolytic, Jan., 74–75
follicular, in acne vulgaris, Jan., 129
Hyperplasia, sebaceous, in elderly, July, 486

Ichthyoses, in childhood, biologic basis of, Jan., **67–78**
lamellar, Jan., 70–73
X-linked, Jan., 73
Ichthyosis vulgaris, in childhood, Jan., 69–70
Immune system, cell-mediated, July, 448
epidermal, aging and, July, **447–454**
ultraviolet radiation and, July, 450
humoral, B cells and, July, 447–448
in atopic dermatitis, in childhood, Jan., 59–60
Immunotherapy, for atopic dermatitis, in childhood, Jan., 64
Incisions, wounds due to, breaking strength of, July, 482
Incontinentia pigmenti, in childhood, Jan., 49–50
Incontinentia pigmenti achromians, in childhood, Jan., 50–51
Infant, bacterial and candidal cutaneous infections in, Jan., **3–21**
Infections, bacterial, and diaper dermatitis, Jan., 25–27
in neonate, Jan., 10–18
in childhood, bacterial and candidal cutaneous, Jan., **3–21**
candidal, Jan., 144–146
fungal, Jan., **137–149**
staphylococcal, in atopic dermatitis, Jan., 61–62
in neonate, candidal sepsis and, Jan., 9
gram-negative, Jan., 15–18
staphylococcal, Jan., 10–14
streptococcal, Jan., 14–15
Interleukin-1, in aging, July, 448–449
Interleukin-2, in aging, July, 448–449
Intertrigo, in elderly, July, 491
Isotretinoin (13–*cis*-retinoic acid), for acne vulgaris, Jan., 133
for ichthyosis, Jan., 73

Kasabach-Merritt syndrome, hemangiomas and, Jan., 82
Kawasaki disease, characteristics of, Jan., 122–123
Keratinocytes, in in-vitro studies of aging, July, 360–361
Keratoacanthoma, in elderly, July, 470
Keratosis, actinic, in sun-induced aging, July, 512, 514
seborrheic, in elderly, July, 485–486
Kidney, failure of, in porphyria cutanea tarda, Apr., 304–305
Klippel-Trenaunay syndrome, in childhood, Jan., 86
KNOWLEDGE-INDEX, for literature searching, Oct., 581

Lakes, venous, in elderly, July, 493
Langerhans cells, density of, aging and, July, 450–452
immune function of, aging and, July, 449, 450
Laser therapy, for hemangiomas, Jan., 81
for port-wine stain, Jan., 86
Leser-Trélat, sign of, in gastrointestinal malignancy, July, 485
Lichen simplex chronicus, in elderly, July, 490
Light, artificial, UVR from, and solar radiation, Apr., 322–323
artificial sources of, apparatus and equipment for, Apr., 210, 211–214
in photosensitivity, Apr., **203–215**
penetration of, into skin, Apr., 174–176
radiant sources of. See *Radiant light sources.*
Lipid peroxidation, in porphyria, Apr., 287–288
Lisch nodules, in neurofibromatosis, Jan., 46
Liver, in heme synthesis, in porphyria, Apr., 284–286
in porphyria cutanea tarda, Apr., 302
tumors of, in porphyria cutanea tarda, Apr., 303–304
Lupus erythematosus, Apr., **267–276**
chronic cutaneous, Apr., 269
in childhood, Jan., **151–160**
discoid, Jan., 156–157
subacute cutaneous, Jan., 157–158
systemic, Jan., 154–156; Apr., 317–318
with porphyria cutanea tarda, Apr., 303
in neonate, Jan., 110, 151–154; Apr., 270–271
lupus band test in, Apr., 267–268
photosensitivity in, pathogenesis of, Apr., 271–272
Ro(SSA) antigen antibody system in, Apr., 268–269
subsets of, Apr., 269–271
systemic, Apr., 269–270
Lymphokines, in aging, July, 448–452
Lymphomatoid granulomatosis, in childhood, Jan., 124

Macules, hypopigmented, in incontinentia pigmenti achromians, Jan., 50
in tuberous sclerosis, Jan., 47
Maffucci syndrome, hemangiomas and, Jan., 84
Medications, antimalarial, in photoprotection, Apr., 337–338
systemic, phototoxicity due to. See *Phototoxicity.*
MEDIS, for literature searching, Oct., 581
MEDLARS, for literature searching, Oct., 579
MEDLINE, for literature searching, Oct., 579–580, 581, 582–587
Melanoblasts, formation of, in embryogenesis, July, 408–409
Melanocytes. See *Pigment cells.*
Melanocytic lesions, in infancy, childhood, and adolescence, Jan., **29–44**
Melanoma, cutaneous malignant, in elderly. See *Elderly, cutaneous malignant melanoma in.*
in childhood, Jan., 39–41
malignant, Jan., 40
dysplastic nevus syndrome and, Jan., 38
vs. congenital melanocytic nevi, Jan., 33–34
vs. Spitz nevi, Jan., 30–32
xeroderma pigmentosum and, Jan., 40
Milia, in sun-induced aging, July, 514
Mucocutaneous lymph-node syndrome (Kawasaki disease), Jan., 122–123
Mucous membranes, oral, candidiasis of, in neonate, Jan., 3–5
MYCIN, to diagnose dermatologic disorders, Oct., 607–610
data entry and display, Oct., 608

MYCIN (*Continued*)
to diagnose dermatologic disorders, medical knowledge, Oct., 608–609
reasoning mechanism, Oct., 609
software, Oct., 609–610
Mycoses, in childhood, deep, Jan., 146–147
superficial, Jan., 137–146

Nails, changes in, in elderly, July, 496
Neonate, acne vulgaris in, Jan., 131
bacterial and candidal cutaneous infections in, Jan., **3–21**
Neural crest, pigment cell formation in, July, 407–408
Neurofibroma, cutaneous, in neurofibromatosis, Jan., 46
Neurofibromatosis, in childhood, Jan., 45–47
Neurones, in in-vitro studies of aging, July, 360
Neutral lipid storage disease, and ichthyosis, Jan., 76
Nevi, formation of, July, 412–415
acquired, July, 413–415
congenital, July, 413
in postnatal life, July, 409
in childhood, congenital melanocytic, Jan., 32–33
vs. malignant melanoma, Jan., 33–34
Spitz, Jan., 29–32
Nevus flammeus, in childhood, Jan., 85–86

Omphalitis, in neonate, Jan., 14
ONCOCIN, for chemotherapy data, Oct., 622
Onychia, candidal, in childhood, Jan., 145
Onychomycosis, in childhood, Jan., 142–143
Ozone layer, and sunburn, Apr., 181

Paper Chase, for literature searching, Oct., 581–582
Parkes-Weber syndrome, in childhood, Jan., 86–87
Paronychia, in childhood, candidal, Jan., 145
in neonate, Jan., 11–12, 14
PATHFINDER, to limit diagnostic errors, Oct., 623
PDQ (Physician's Data Query), for literature searching, Oct. 580
Peels, trichloroacetic acid and phenol, for wrinkles, in elderly, July, 497
Pellagra, in childhood, Apr., 313–314
Pemphigus, in childhood, Jan., 96
Periarteritis nodosa, in childhood, Jan., 120–121
Perleche, in childhood, Jan., 145
Phenol, for wrinkles, in elderly, July, 497
Photoaging, July, **517–526**. See also *Aging, sun-induced.*
action spectrum of, experimental studies of, July, 519–523
infrared radiation and photoaging, July, 523
solar simulating radiation and photoaging, July, 522–523
UVA and photoaging, July, 521–522
UVB and photoaging, July, 519–521
prevention of, sunscreens in, July, 523–524, 526
therapy for, July, 526
vs. aging, histologic comparisons of, July, 517–519
Photoallergy, drug-induced, Apr., **231–241**
action spectra for, Apr., 235
agents causing, Apr., 232–233
clinical characteristics of, Apr., 237
diagnosis of, Apr., 238
differential diagnosis of, Apr., 238–239
immunologic characteristics of, Apr., 235–237
pathogenetic mechanisms of, Apr., 233–237
photoantigen formation in, Apr., 233–235
systemic medications in, Apr., 237
treatment of, Apr., 239
vs. phototoxic reactions, Apr., 231–232
Photobiology, basic science of, Apr., **171–179**
Photoeruptions, in childhood, Jan., 110–115
Photoirritation, due to topical agents, Apr., **217–222**
alternate testing methods in, Apr., 220–221
animal testing methods in, Apr., 218, 219
chemical-skin contact time in, before light exposure, Apr., 219–220
cutaneous metabolism in, Apr., 220
effect of vehicles on, Apr., 220
human testing methods in, Apr., 219
morphology of, Apr., 217
nomenclature of, Apr., 217
oral chemicals in, Apr., 221
pharmacology of, Apr., 217–218
phototoxic agents in, Apr., 218–219
untreated natural history of, Apr., 217
wavelengths in, Apr., 218
Photopatch testing, for sensitivity diseases, Apr., 197–201
light source for, Apr., 200
patient instructions for, Apr., 200–201
potential allergens to be tested, Apr., 198–200
procedure for, Apr., 198
recording and interpretation of, Apr., 201
Photoproducts, and biochemical and cellular changes, Apr., 178–179
Photoprotection, antimalarial drugs in, Apr., 337–338
nonsunscreen, Apr., 331–332
oral psoralens in, Apr., 338
sunscreens in, Apr., **321–334**
systemic, Apr., **335–339**
Photosensitivity, Apr., **167–339**
artificial sources of light in, Apr., **203–215**
chronic, Apr., **261–266**
disorders of, actinic prurigo, Apr., 263
actinic reticuloid, Apr., 262–263
persistent light reaction, Apr., 261–262
photosensitive eczema, Apr., 262
investigation of, Apr., 263–264
treatment of, Apr., 264–265
classification of, Apr., **167–169**
evaluation of patient with, Apr., **195–202**
examination in, Apr., 196
history in, Apr., 195–196
photopatch testing in, Apr., 197–201
phototesting in, Apr., 196–197
in infants and children, Apr., **311–319**
in lupus erythematosus, Apr., 271–272
in porphyria, Apr., 286–288
photodermatitis and, in childhood, Jan., **107–116**
Phototesting, for sensitivity diseases, Apr., 196–197
for solar urticaria, Apr., 256
Phototoxicity, due to oral chemicals, Apr., 221
due to systemic agents, Apr., **223–230**
clinical characteristics of, Apr., 223–224
diagnosis of, Apr., 228
mechanism of action of, Apr., 227–228
medicinal, Apr., 224–227
amiodarone, Apr., 226–227
antibiotics, Apr., 225
chemotherapeutic agents, Apr., 226
chlorpromazine, Apr., 225
diuretics, Apr., 226
hematoporphyrin, Apr., 226
isotretinoin, Apr., 225–226
nonsteroidal anti-inflammatory drugs, Apr., 225

psoralens, Apr., 224–225
sulfanilamide, Apr., 224
sulfonylureas, Apr., 226
treatment of, Apr., 228–229
vs. photoallergic reactions, Apr., 231–232
Pigment cells, in choroid, July, 416
in embryogenesis, dermal, July, 408–409
epidermal, July, 410
in hair follicles, July, 411
in postnatal life, dermal, July, 409–410
epidermal, July, 410–411
in hair follicles, July, 411–412
in retinal pigment epithelium, July, 415–416
lives of, July, **407–418**
origin of, July, 407–408
Pigmentation, irregular, in sun-induced aging, July, 512
Pityriasis amiantacea, in childhood, Jan., 104
Poikiloderma congenitale, characteristics of, Jan., 114–115; Apr., 315–316
Polymorphous light eruption, Apr., **243–251**
clinical and histologic manifestations of, Apr., 244–246
diagnosis of, Apr., 246–248
differential diagnosis of, Apr., 246–248
etiology and pathogenesis of, Apr., 243–244
in childhood, Jan., 110–111
incidence of, Apr., 244
treatment of, Apr., 248–249
Polyps, fibroepithelial (skin tags), in elderly, July, 486
Porphyria, basic science aspects of, Apr., **277–290**
complement activation in, Apr., 288
delta-aminolevulinic acid synthase in, Apr., 277–284
erythropoietic, Apr., **291–296**
congenital, Apr., 291–293
heme synthesis in, regulation of, Apr., 284–286
in childhood, Jan., 111–112; Apr., 312–313
lipid peroxidation in, Apr., 287–288
photosensitization in, mechanisms of, Apr., 286–288
variegate, vs. porphyria cutanea tarda, Apr., 304
Porphyria cutanea tarda, Apr., **297–309**
and hepatic tumors, Apr., 303–304
biochemical abnormalities in, Apr., 301–302
cutaneous histopathology of, Apr., 302
cutaneous manifestations in, Apr., 300–301
differential diagnosis of, Apr., 304, 305
environmental factors in, Apr., 303
etiologic factors in, Apr., 302–303
hepatic histopathology of, Apr., 302
laboratory diagnosis of, Apr., 298–299
photocutaneous pathophysiology of, Apr., 299–300
porphyrin biosynthesis in, Apr., 297–298
treatment of, Apr., 305–306
with chronic renal failure, Apr., 304–305
with systemic lupus erythematosus, Apr., 303
Port-wine stain (neveus flammeus), in childhood, Jan., 85–86
Postnatal life, pigment cell formation in, July, 409–412
Protoporphyria, erythropoietic, Apr., 293–295
beta-carotene therapy for, Apr., 335–337
Prurigo nodularis, in elderly, July, 490
Pruritus, in elderly, July, 489–490
Pseudomonas aeruginosa infections, in neonate, Jan., 15–18
Pseudoporphyria, drug-related, vs. porphyria cutanea tarda, Apr., 305
Psoriasis, in childhood, Jan., **99–106**
clinical features of, Jan., 101–103
differential diagnosis of, Jan., 103
genetics of, Jan., 99–100
incidence of, Jan., 99
inciting factors in, Jan., 100–101
treatment of, Jan., 104–105
vs. ichthyosis, Jan., 68–69
in neonate, and diaper dermatitis, Jan., 27
Psoriatic arthritis, in childhood, Jan., 102–103
Purpura, senile, in elderly, July, 493
PUVA, for chronic photosensitivity, Apr., 265
for solar urticaria, Apr., 258
in tanning, Apr., 192

Radiant light sources, comparison of, Apr., 203, 205–210
carbon arc, Apr., 205
fluorescent lamps, Apr., 207–209
hot quartz lamp, Apr., 206
incandescent lamps, Apr., 209
lasers, Apr., 209–210
mercury vapor lamps, Apr., 206–207
Wood's lamp, Apr., 206–207
xenon arcs, Apr., 205–206
measurement of, radiometer for, Apr., 203–204
Radiation, infrared, and photoaging, July, 523
nonionizing, Apr., 172–174
interaction with chromophores in skin, Apr., 176–178
solar, and UVR due to artificial light, Apr., 322–323
solar simulating, and photoaging, July, 522–523
ultraviolet, and epidermal immunology, July, 450
and photoaging, July, 514–515, 519–522
environmental sources of, Apr., 210
Radiometer, to measure radiant light source, Apr., 203–204
Random-access memory (RAM), definition of, Oct., 537
Read-only memory (ROM), definition of, Oct., 537
Refsum's syndrome, characteristics of, Jan., 75
Respiratory tract, obstruction of, hemangiomas and, Jan., 82
Rhinophyma, clinical presentation of, July, 492
Riley-Smith syndrome, in childhood, hemangiomas and, Jan., 85
Rothmund-Thomson syndrome (poikiloderma congenitale), characteristics of, Jan., 114–115

S-transferases, against oxidative free radical damage, in biologic aging, July, 351–352
Sacral spot, formation of, in postnatal life, July, 409–410
Salmon patch, in neonate, Jan., 85
Scales, formation of, in ichthyosis, Jan., 71–73
Scalp hair, computer-aided quantification of, Oct., **627–640**
algorithm for, Oct., 627–628
methods of, Oct., 628–637
binary thresholding, Oct., 630
illustration of, Oct., 630, 637
image analysis, Oct., 628
statistical model, Oct., 628–630
results of, Oct., 637–638
Scars, due to acne vulgaris, treatment of, Jan., 134
Sclerosis, tuberous, in childhood, Jan., 47–48
Sebaceous glands, in acne vulgaris, Jan., 127–128
Sebum, secretion of, changes in, July, **419–423**
declining, clinical significance of, July, 422
in males vs. females, July, 420
measurement of, July, 419–420
ultimate levels of, July, 421–422
variation with age, July, 420–422
Sensitivity disease, evaluation of patient with, laboratory studies in, Apr., 201
Shagreen patch, in tuberous sclerosis, Jan., 48

Shingles, in elderly, July, 492–493
Sjögren-Larsson syndrome, in childhood, Jan., 75
Skin, aged. See also *Aging; Elderly.*
barrier properties of, July, 425–426
cancer of. See *Elderly, skin cancer in.*
cell turnover in, July, 429–430
common problems of. See *Elderly, common skin problems in.*
connective tissue biochemistry of, July, **433–446**. See also *Collagen; Elastin.*
elastic fiber and microvascular abnormalities in, July, **391–405**
elastic fiber network in, July, 391–397
components of, July, 391–392
electron microscopic studies of, July, 392–397
light microscopic studies of, July, 392
inflammatory response in, July, 426–427
integumental reactivity of, July, 426–427
microvasculature in, July, 397–400, 426
electron microscopic studies of, July, 398–400
light microscopic studies of, July, 397–398
morphology of, July, **379–389**
collagen, July, 383–386
dermis, July, 382–383
elastin, July, 386
epidermis, July, 379–382
of buttocks, electron microscopic studies of, July, 399–400
of extensor forearm, July, 398–399
pain perception in, July, 427
percutaneous absorption in, July, **455–465**
critique of literature on, July, 459–460
current studies on, July, 461–464
review of literature on, July, 455–459
physiologic changes in, July, **425–432**
structural observations of, July, 437–438
vulnerability of, July, 428
wound repair in. See *Wounds.*
dry, declining sebum secretion and, July, 422
grafting of, in sun-induced aging, July, 511–512
tumors of, in elderly, July, 485–488
types of, and reaction to sun, Apr., 183, 189–190, 323–324
Software, computer. See *Computer software.*
Spitz nevi, clinical forms of, Jan., 30
in childhood, Jan., 29–32
vs. malignant melanoma, Jan., 30–32
Staphylococcal infections, in neonate, Jan., 10–14
Staphylococcus aureus, and atopic dermatitis, Jan., 61–62
and diaper dermatitis, Jan., 27
Steroids, for atopic dermatitis, Jan., 63
intralesional, for acne vulgaris, Jan., 133
Stomatitis, angular, in elderly, July, 491–492
Streptococcal infections, in neonate, Jan., 14–15
Sturge-Weber syndrome, in childhood, Jan., 86
Sun, effects of, on aging. See *Aging, sun-induced; Photoaging.*
sensitivity reactions to, in childhood, Jan., 109–110
Sunburn, alteration of response to, topical and systemic drugs in, Apr., 185–186
environmental factors in, Apr., 181–182
histology of erythema in, Apr., 185
individual sensitivity to, Apr., 183
pathophysiology of, Apr., 183–185
physiology of, Apr., **181–187**
prevention of, under adverse conditions, Apr., 332–333
types of UV erythema in, Apr., 182–183
Sunscreens, for sun-induced skin reactions, Apr., **321–334**
in health and disease, Apr., 328–331
sun protection factor in, Apr., 325–328
systemic, Apr., 330–331
to prevent photoaging, July, 523–524, 526
topical, Apr., 324–328
adverse effects of, Apr., 333
Superoxide dismutase, against oxidative free radical damage, in biologic aging, July, 350
Surgery, cosmetic, for wrinkles, in elderly, July, 497

Tanning, adverse reactions to, Apr., 192
artificial radiation sources for, Apr., 190
inducible photoprotection in, Apr., 191
photobiologic aspects of, Apr., **189–193**
pigment responses to UV radiation in, Apr., 190–191
skin types and, Apr., 189–190
TEGUMENT, for dermatopathologic diagnosis, Oct., 620
Telangiectasia, in sun-induced aging, July, 512
Telecommunications, computers in, Oct., 542
new advances in, Oct., 667
Thrush, in neonate, Jan., 3–5, 144
Tinea capitis, characteristics of, Jan., 138–141
Tinea corporis, in childhood, Jan., 137–138
Tinea cruris, in childhood, Jan., 137–138
Tinea pedis, in childhood, Jan., 141–142
Tinea unguium (onychomycosis), in childhood, Jan., 142–143
Tinea versicolor, in childhood, Jan., 143–144
Toxic shock syndrome, in neonate, Jan., 13
Transplantation, of hair, July, 495
skin graft, in sun-induced aging, July, 511–512
Tretinoin (retinoic acid), for acne vulgaris, Jan., 132
Tuberous sclerosis, in childhood, Jan., 47–48
Tumors, hepatic, in porphyria cutanea tarda, Apr., 303–304
incidence of, in aging U.S. population, July, 374
of skin, in elderly, July, 485–488

Ulceration, hemangiomas and, in childhood, Jan., 81
Ulcers, stasis, in elderly, July, 493–494
Ultraviolet radiation, and epidermal immune system, July, 450
and photoaging, July, 514–515, 519–522
Urticaria, due to irradiated photoallergens, Apr., 256
IgE-mediated, Apr., 253
solar, Apr., **253–259**
clinical features of, Apr., 256
etiology and pathogenesis of, Apr., 253–254
in childhood, Jan., 111
inhibition spectrum in, Apr., 255
location of active photochemical in, Apr., 254
passive and reverse-passive transfer in, Apr., 255
photochemistry in, Apr., 254
phototesting in, Apr., 256
solar vasculitis in, Apr., 255–256
treatment of, Apr., 257–258
wavelength of light in, Apr., 254

Vascular lesions, in childhood, Jan., **79–87**
Vascular stains, in childhood, Jan., 85–87
Vasculitides, in childhood, Jan., **117–125**
Veil cells, function of, in aged skin, July, 403–404
Veins, spider, in elderly, July, 493

von Hippel–Lindau disease, hemangiomas and, in childhood, Jan., 84
Vulvovaginitis, in childhood, Jan., 145

Wegener's granulomatosis, in childhood, Jan., 123
Wiskott-Aldrich syndrome, characteristics of, Jan., 60
Wounds, healing of, aging and, July, 481–484, 428–429
  clinical observations of, July, 481–482
  subclinical evidence of, July, 482–483
Wrinkles, development of, in elderly, July, 496–497

Xeroderma pigmentosum, in childhood, Jan., 39–40, 48–49, 112–113, Apr., 311–312